

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

WO 98/01472

(51) International Patent Classification 6 : C07K 14/575		A1	(11) International Publication Number: WO 98/01472
(21) International Application Number: PCT/CA97/00481		(43) International Publication Date: 15 January 1998 (15.01.98)	
(22) International Filing Date: 7 July 1997 (07.07.97)		(81) Designated States: European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/682,810 10 July 1996 (10.07.96) US		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant: ADVANCED BIOCONCEPT, INC. (CA/CA); Suite 424, 1440 Sainte-Catherine West, Montreal, Quebec H3G 1R8 (CA).			
(72) Inventors: FAURE, Marie-Pierre; 2286 Frenette, Ville St Laurent, Quebec H4R 1M2 (CA). VINCENT, Jean-Pierre; Le Saigne D-Domaine du Loup, F-06800 Cagnes-sur-Mer (FR). GAUDRIAULT, Georges; L.P. Les Palmiers, Boite postale 257, F-06305 Nice Cedex 4 (FR). BEAUDET, Alain; 39 Surrey Drive, Mount Royal, Quebec H3P 1B2 (CA). DESJARDINS, Clarisse; 4400 Champlain Boulevard 118, Verdun, Quebec H4G 1A9 (CA).			
(74) Agents: ROBINSON, J., Christopher et al.; Smart & Biggar, Box 11560, Vancouver Centre, Suite 2200, 650 W. Georgia Street, Vancouver, British Columbia V6B 4N8 (CA).			
<p>(54) Title: FLUORESCENT PEPTIDES</p> <p>(57) Abstract</p> <p>The invention provides biologically active compounds of formula (I) where R₁ is a light-emitting moiety and R₂ is a peptide of between 2 and 200 amino acids. X is selected from the group including -O-, -S-, -OH, -C=O-, -NH-, -H-, -OR-, -NR-, -R-, -R₃R₄, wherein each R, R₄ and R₃, independently, is H or a C₁-C₆ branched or unbranched, substituted or unsubstituted, alkyl. The compounds are both biologically active and optically detectable. The peptide is chemically attached to the light-emitting moiety at an amino acid position which is not involved in binding to the peptide's receptor. In this way, the peptide's affinity for its receptor is not significantly decreased, and the compound retains high biological activity and can be easily detected using standard optical means.</p> <p style="text-align: right;">X R₁ - C - R₂ (I)</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SE	Sweden
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GZ	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BI	Burundi	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NR	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroun	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

FLUORESCENT PEPTIDESBackground


5 This application is a continuation-in-part of U.S.S. No. 08/504,856, filed July 20, 1995 and entitled "Fluorescent Peptides", which is a continuation-in-part of U.S.S.N 08/475,751, filed June 7, 1995 and entitled "Fluorescent Somatostatin", which is a continuation-in-part of U.S.S.N. 08/416,007, having the same name and filed April 4, 1995.

10 This invention relates to peptide-based compounds having light-emitting moieties. Detectably labelled peptides provide useful reagents for monitoring peptide, cytokine, drug, and hormone receptors at the cellular level. Typically, the labelled peptide is placed in contact with a tissue or cell culture where it binds an available receptor. Once bound, the label is detected, allowing properties such as receptor 15 distribution or receptor binding kinetics to be monitored.

Summary of the Invention

20 The invention provides a compound containing a peptide and a light-emitting moiety which is both biologically active and optically detectable. The peptide is chemically attached to the light-emitting moiety at an amino acid position which is not involved in binding to the peptide's receptor. In this way, the peptide's affinity for its receptor is not significantly decreased, and the compound retains high biological activity and can be easily detected using standard optical means.

25 In general, in one aspect, the invention provides a biologically active compound of the formula:




30 where R_1 is a light-emitting moiety; R_2 is a peptide of between 2 and 200 amino acids which is not neurotensin; and X is selected from the group consisting of $=O$, $=S$, $-OH$, $=C=O$, $=NH$, $-H$, $-OR$, $-NR$, $-R$, $-R_3R_4$, wherein each R , R_4 , and R_3 , independently, is H or

SUBSTITUTE SHEET (RULE 26)


-2-

a C1-C6 branched or unbranched, substituted or unsubstituted, alkyl. In another aspect, the invention provides a biologically active compound of the formula:



where R₁ is a light-emitting moiety and R₂ is a peptide of between 2 and 200 amino acids bound to C by a binding moiety selected from the group including the residues Ala, Arg, Asn, Asp, Cys, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val. Preferably, in this case, the peptide R₂ is not neuropeptidin. In both cases, X is selected from the group including =O, =S, -OH, =C=O, =NH, -H, -OR, -NR, -R, -R₃R₄, wherein each R, R₄ and R₃, independently, is H or a C1-C6 branched or unbranched, substituted or unsubstituted, alkyl.

In yet another aspect, the invention provides a biologically active compound of the formula:



where R₁ is a light-emitting moiety, R₂ is a peptide of between 2 and 200 amino acids, and X is selected from the group consisting of =O, -OH, =C=O, =NH, -H, -OR, -NR, -R, -R₃R₄, where each R, R₄ and R₃, independently, is H or a C1-C6 branched or unbranched, substituted or unsubstituted, alkyl. Preferably, in this case, the peptide R₂ is not neuropeptidin.

In other aspects, a C1-C6 branched or unbranched, substituted or unsubstituted, alkyl serving as a "linker group" is disposed between the R₂ and C-X moieties. In this case, R₂ is preferably an opioid peptide and R₁ is preferably -NH(CH₂)₂NH-. In still other aspects, R₂ is neuropeptidin or an analogue thereof.

In preferred embodiments, both R₁ and R₂ are selected from the group including adrenocorticotropic hormone, amylin, an amyloid beta-fragment, an atrial natriuretic peptide, bombesin, bradykinin, cadherin, calcitonin, a calcitonin-gene-related peptide, a casomorphin, a morphiceptin, cholecystokinin, corticotropin-releasing factor, deltorphin, a dermorphin, dynorphin, an endorphin, endothelin, enkephalin, fibronectin, galanin, a

-3-

gonadotropin-associated peptide, a gonadotropin-releasing peptide, a growth factor or growth factor-related peptide, gastrin, glucagon, growth hormone-releasing factor, somatostatin, a GTP-binding protein fragment, inhibin, insulin, interleukin, lutenizing hormone-releasing hormone, magainin, melanocyte-stimulating hormone, a morphiceptin, a neuropeptide, a neuromedin, neuropeptide-Y, an opioid peptide, oxytocin, a pancreatic polypeptide, a parathyroid hormone, a vasoactive intestinal polypeptide, Peptide YY, substance P, thyroid-releasing hormone, a toxin, vasopressin, and fragments, derivatives, and analogs thereof. Other possibilities for R₂ or R₇ are described in detail below. Most preferably, R₂ or R₇ are selected from the group consisting of endothelin and galanin.

In preferred embodiments, C is bonded to R₁ through an amino residue of an alpha carbon atom. Most preferably, R₁ is bound, through C, to a region of the R₂ peptide which is not involved in the peptide's biological activity, and the R₂ peptide binds to a human receptor.

In particular examples, R₂ is endothelin, and R₁ is bonded, through C, to the ninth amino acid residue of R₂ (e.g., the ε-amine group of Lys). If R₁ is galanin then R₁ is bonded, through C, to the fifth amino acid residue of R₂ (e.g., the ε-amine group of Lys).

In other preferred embodiments, R₁, the light-emitting moiety, is selected from the group including fluorescein, FTC, Texas Red, phycoerythrin, rhodamine, carboxytetramethylrhodamine, DAPI, indopyra dyes, Cascade blue coumarin, NBD, Lucifer Yellow, propidium iodide, a porphyrin, BODIPY, CY³, CY⁵, CY⁹, and derivatives and analogs thereof. R₁ can be attached to C-X through a linking moiety selected from the group including indoacetamide, maleimide, isothiocyanate, succinimidyl ester, sulfonyl halide, aldehyde, glyoxal, hydrazine, and derivatives thereof.

In yet another aspect, the invention provides a method for generating a biologically active compounds described above. The method includes the steps of reacting R₁ and R₂ in an aqueous solution to form a compound mixture; contacting the compound mixture with a receptor for R₂; and isolating from the compound mixture a compound exhibiting biological activity in the presence of the R₂ receptor.

Preferably, the isolating step includes the steps of binding the compound to the R₂ receptor; releasing the compound from the binding complex; and isolating the biologically active complex.

-4-

In another aspect, the invention provides a method for generating a biologically active compound of claim 1 which includes the steps of reacting R_1 and R_2 in an aqueous solution to form a compound mixture; contacting the compound mixture with a receptor for R_2 ; isolating from the compound mixture a compound exhibiting biological activity in the presence of the R_2 receptor; determining biologically inactive regions of the isolated compound; and synthesizing one of the above-described compounds by chemically attaching the light-emitting moiety to an amino acid comprised in the biologically inactive region. The final compound is then formed by attaching all other amino acids to form R_2 .

In still other aspects of the invention, the above-described compounds are used for labelling cell receptor sites, cell sorting, flow cytometry, and performing fluorimmunoassays. For example, cell receptor sites can be imaged by contacting candidate cell receptor sites with one of the above-described compounds, and then detecting the bound compounds as an indication of the cell receptor sites. Cell sorting can be performed by contacting a population of candidate cells with an above-described compound, and isolating cells bound to the compound. Flow cytometry can be performed by contacting a population of cells with an above-described compound, and detecting cells bearing receptors on their surfaces by detecting cells bound to the compound.

In all cases, by "biologically active" is meant the compound binds to a receptor having an affinity (IC_{50} value) for the compound which is at least 15 times that of the corresponding unlabelled peptide. More preferably, the IC_{50} value for the compound is at least 10 times that of the corresponding unlabelled peptide. Most preferably, the IC_{50} value for the compound is equal to or less than that of the corresponding unlabelled peptide. Receptor affinity, in this case, can be determined either using methods involving competition binding with radioactively labelled peptides or by using known methods of fluorescence polarization for measuring K_d for the receptor-peptide interaction or other fluorescence techniques for measuring K_d .

By "peptide", as used herein, is meant a chain of amino acids of any length. Included in this term are proteins and polypeptides.

-5-

By "compound mixture", as used herein, is meant a mixture of peptides which are bound to light-emitting moieties at different amino acid positions. Such a mixture may contain peptides of varying lengths and varying biological activities.

The invention has many advantages. In a general sense, peptide-containing compounds which retain their biological activity after being labelled with light-emitting moieties have a wide variety of biological applications. Such compounds can be used effectively to identify, visualize, quantify, target, and select receptors on cells and tissues both *in vitro* and *in vivo*. These compounds obviate the use of more conventional labelled peptides, e.g., those attached to radioactive isotopes such as ^{125}I . Radiolabelled compounds are often toxic, environmentally hazardous, chemically unstable, and have, by nature of the isotopes' radioactive decay rates, relatively short lifetimes. In contrast, the light-emitting biologically active compounds of the invention are relatively safe, non-toxic, easily disposable, and may be synthesized without employing any special laboratory procedures. In addition, because most light-emitting moieties are relatively stable, the compounds can be stored for extensive periods of time without undergoing significant degradation.

The compounds of the invention offer many additional advantages when employed in biological experiments. For example, peptides labelled with light-emitting moieties emit optical signals following excitation, and thus may be monitored by eye or with the aid of conventional, easy-to-use optical detectors (e.g., conventional charge-coupled devices (CCDs) or light-sensitive cameras). This method of detection is, in general, relatively simple and cost effective compared to detection of radioactive particles.

In addition, unlike radiolabelled, enzymatic, and colorimetric compounds, the compounds of the invention do not have to be incubated with secondary labelled compounds for detection. This means that the compounds can be used to monitor dynamic biological phenomena, such as the kinetics associated with receptor binding, in real time.

Furthermore, selection of biologically active compounds using a receptor binding assay is advantageous because it allows generation of useful biological labels in a rapid and efficient manner. In contrast, radiolabelled peptides typically require distinct and

-6-

time-intensive steps for first isolating the labelled peptides and then determining their biological activity.

Other advantages and features of the invention will become apparent from the following detailed description, and from the claims.

5

Brief Description of the Drawings

Fig. 1 is a schematic drawing of a compound containing a peptide and light-emitting moiety according to the invention;

Fig. 2 is a flow chart showing the general synthetic procedure used to produce the compounds of the invention;

10 Fig. 3 is a schematic drawing of the chemical structure of fluorescent endothelin-1 according to the invention;

Fig. 4 is a schematic drawing of the chemical structure of fluorescent galanin according to the invention;

15 Figs. 5A and 5B are, respectively, CLSM and computer-generated images showing fresh, frozen rat cerebellum sections imaged with fluorescent endothelin; and,

Figs. 6A and 6B are, respectively, CLSM and computer-generated images showing fresh, frozen rat brain septal regions imaged with fluorescent galanin.

Detailed Description

20 As discussed above and shown in Fig. 1, biologically active and light-emitting, peptide-based compounds 10 according to the invention are generated by attaching a light-emitting moiety 12, such as a fluorescent dye, through a -(C-X)- bond to a peptide moiety 14. The peptide moiety contains both a biologically active region 16 and one or more "inactive" regions 18 (i.e., regions that are not significantly involved in the peptide's biological role). In one particular example, the biologically active region binds to the peptide's associated receptor, while the biologically inactive regions do not significantly participate in the peptide/receptor binding process. In general, to retain a biological activity for a fluorescent peptide that is comparable to that of the native peptide, the light-emitting moiety is chemically attached at a site within one of the peptide's biologically inactive regions. In this manner, the light-emitting moiety does not sterically hinder or 25 otherwise significantly affect the region involved in, for example, receptor binding, and the biological activity of the compound is thus maintained at a high level.

30

-7-

In general, because of their relatively small size, the compounds of the invention preferably exhibit a 1:1 molar ratio between the light-emitting and peptide moieties. The attachment of more than one light-emitting moiety per peptide may, in some cases, result in a loss of biological activity. The 1:1 molar ratio is also important for the quantification of receptors during labelling applications, as it allows measured fluorescence intensity to be directly translated into a measure of binding peptide moieties which, in turn, allows the number of receptors to be determined. In addition, multiple fluorophores attached to a single peptide may result in fluorescence quenching, i.e., a loss of emission intensity which sometimes occurs when fluorophores are present in very close proximity to each other.

In addition to having amino acids available for receptor binding, the peptide compounds of the invention also contain light-emitting moieties which retain optical properties similar to those of the unbound fluorophore. In this way, the compound, even when bound to its receptor, emits light following absorption of an incident optical field, and thus serves as a marker for that particular receptor.

The general synthetic method for generating light-emitting biologically active compounds of the invention is shown in Fig. 2. This method begins with the step 20 of incubating the peptide and fluorophore of choice to form a mixture of compounds. Incubation is performed under conditions which permit optimal peptide labelling (see below). Typically, a solution containing the peptide of choice (preferably at a concentration of 10^{-2} - 10^{-4} M) is mixed with the light-emitting moiety in a highly basic solution (i.e., at a pH of 9.3-10.7), such as a carbonate buffer, in at least a 1:4 peptide:light emitting moiety molar ratio. The solution is mixed at room temperature for a time period of between about 24-48 hours, and is protected from light and shaken periodically. The resulting compound mixture includes biologically active and inactive whole peptides, cleaved fragments of peptides, and singly and multiply labelled peptides.

After covalent conjugation between the light-emitting moiety and peptide is allowed to occur, unbound fluorophore is removed (step 22). In general, this selection process can be performed using standard techniques, such as column chromatography or other analytical techniques known in the art. In a typical example, unreacted amounts of the free fluorophore are removed using a G-50 column equilibrated with phosphate-

-8-

buffered saline (pH 7.4) and spun at 3000 rpm for a time period of between 5 and 20 minutes. The resultant eluent contains a mixture of labelled biologically active and inactive peptides.

5 This solution is then collected and subjected to a high-stringency pharmacological binding assay (step 24). In this assay, only biologically active compounds are bound to tissue receptors; inactive compounds are washed away. The assay is typically performed on tissue sections, receptor-coated columns, or membrane homogenates. In a typical example, an aliquot of the fluorescent peptide mixture is first dissolved in an aqueous solution (1:100) and incubated with an immobilized tissue sample containing high 10 numbers of the peptide's receptor, e.g., receptor transfected membrane homogenates.

15 The selection process is designed to separate compounds exhibiting substantial biological activity from those relatively inactive compounds. If necessary, during the assay, binding of the biologically active compounds may be rapidly observed visually (from the sections or cells), in a fluorometer (from precipitated membrane homogenates), or by using more sensitive techniques such as fluorescence polarization spectroscopy.

The receptor-bound compounds are then removed from the tissue surface (step 26) and analyzed (step 28) to identify the site at which the fluorophore is attached (i.e., the site allowing fluorophore attachment without interference with receptor binding).

20 Biologically active compounds bound to membrane receptors are separated from the remaining inactive fluorescent peptides in solution, either by centrifugation of membrane homogenates (typically at 3000 rpm for about 5 minutes at 4°C) or, in the case of sections, by rapidly rinsing the sections in incubation buffer (3 x 1 minute) at 4°C. The membranes are then resuspended in binding buffer, with the biologically active compounds removed from the cell surface by incubation in a high salt/acid wash solution.

25 Once isolated, biologically active compounds are analyzed using known techniques, such as carboxypeptidase digestion and capillary electrophoresis, laser induced capillary zone electrophoresis, mass spectrometry, and/or HPLC or amino acid sequencing, to identify the site of attachment between the light-emitting moiety and the peptide.

-9-

Once the attachment site is determined, the appropriate amino acid can be attached directly to the light-emitting moiety prior to synthesis of the peptide. This allows the compound to be synthesized in a highly purified form using standard techniques, such as solid-phase peptide synthesis (step 30). If desired, the resulting complex can be further purified (step 32), preferably using a column-based method such as HPLC, and then eluted. In this manner, large quantities of biologically active, labelled peptide compounds can be easily generated in an automated fashion.

In general, reactions between peptides and light-emitting moieties are carried out by modifying amino acid functional groups, most typically a thiol or amine group, so that the moieties may be easily conjugated. Reactions for such modifications are described in the "Handbook of Fluorescent Probes and Research Chemicals - 5th Edition" by Richard P. Haugland (1992), the contents of which are incorporated herein by reference. In general, thiols react with alkylating groups (R'-Z) to yield relatively stable thiol ethers (R-S-R'), with the leaving group Z preferably being a halogen (e.g., Cl, Br, or I) or a similar moiety. The most common reagents for derivatization of thiols are haloacetyl derivatives. Reaction of these reagents with thiols proceeds rapidly at or below room temperature in the physiological pH range.

Light-emitting moieties may also be attached to amino acid amine groups. The conditions used to modify amine moieties of the desired peptide will depend on the class of amine (e.g., aromatic or aliphatic) and its basicity. Aliphatic amines, such as the α -amino group of lysine, are moderately basic and reactive with acylating reagents. The concentration of the free-base form of aliphatic amines below pH 8 is very low; thus, the kinetics of acylation reactions of amines by isothiocyanates, succimidyl esters, and other reagents is strongly pH-dependent. Although amine acylation reactions should usually be carried out above pH 8.5, the acylation reagents degrade in the presence of water, with the rate increasing as the pH increases. The α -amino function of the amino terminus usually has a pK_a of ~ 7, thereby allowing it to be selectively modified by reaction at neutral pH.

In general, reactive groups on the light-emitting moiety, such as unsaturated alkyl groups, will react with the modified amino acid to form the compounds of the invention. The chemical structure of the light-emitting moiety may affect the synthetic route used to

-10-

synthesiz the compound. It may be necessary, for example, to modify the light-emitting moiety so that it includes a reactive group prior to exposure to the desired peptide.

The above technique has been used to synthesiz a biologically active compound containing somatostatin and a light-emitting moiety which is described in U.S.S.N. 5 08/475,751 entitled "Fluorescent Somatostatin", filed June 7, 1995, which is a continuation-in-part of U.S.S.N. 08/416,007, having the same name and filed April 4, 1995, the contents of which are incorporated by reference.

Figs. 3 and 4 show two different compounds made by the general method described above. Each compound features fluorescein, a light-emitting moiety, bound to 10 an individual peptide at an amino acid position which preserves the compound's biological activity. In each of these compounds, the C-X bond is an acyl moiety. Table 1, below, lists the peptides and fluorescein-bound amino acids included in each of the compounds.

15 **Table 1 - Biologically Active Light-Emitting Compounds**

Figure	Peptide	Binding Amino Acid	Light-emitting moiety
3	Endothelin I	9; ϵ amine - Lys	fluorescein
4	Galanin	5; ϵ amine - Lys	fluorescein

20 The syntheses of the compounds of Table 1, along with biological experiments describing their applications, are described in detail in the Examples below.

In general, any peptide which exhibits an affinity for its corresponding receptor can be used to make a biologically active light-emitting compound of the invention. Peptides may be synthesized using techniques known in the art, extracted from natural systems, or obtained from commercial sources (e.g., Peninsula, Neosystems, Sigma, and 25 BASF). Typically, the peptide is either purchased or synthesized using conventional solid-phase synthetic techniques. Preferably, the peptide is substantially pure, meaning that it is at least 60% by weight free from the other compounds with which it is naturally associated.

-11-

5 In certain peptides, the carboxy terminus is the only part of the molecule which can be attached to a fluorophore without disrupting the peptide's biological activity. In these cases, it is therefore necessary to add a separate "linker" group to the peptide. Since the N-hydroxysuccinimide esters (NHS) or isothiocyanate forms of fluorophores do not readily react with carboxylic groups or carboxyl amine groups, these groups must first be modified to provide a functional site (e.g., a primary amino group) for conjugation with fluorophores. For example, fluorescent opioid peptides include linker groups to maintain their biological activity. In this case, an aminopentyl group is grafted onto the C-terminal amino acid by aminolysis of the opioid peptide with 1,5-diaminopentane as described 10 below. Aminopentyl linker groups can also be added to a peptide when the peptide is incubated with carbodimides. Water soluble carbodimides are widely used for carboxyl-amine conjugation and may also serve to link fluorophores to the carboxy terminus of peptides.

15 Whether or not to include a linker group is usually determined empirically by testing a fluorescent peptide labelled at various amino acid sites and finding that it has lost biological activity. For some peptides, structure-activity studies show that the entire amino terminus and central portion of the peptide are involved in receptor binding. This suggests that only the carboxy terminus of the peptide can be modified without disrupting biological activity.

20 Preferred peptides are included in the group consisting of adrenocorticotrophic hormone, amylin, an amyloid beta-fragment, an atrial natriuretic peptide, bombesin, bradykinin, cadherin, calcitonin, a calcitonin-gene-related peptide, a casomorphin, a morphiceptin, cholecystokinin, corticotropin-releasing factor, deltorphin, a dermorphin, dynorphin, an endorphin, endothelin, enkephalin, fibronectin, galanin, a gonadotropin- 25 associated peptide, a gonadotropin-releasing peptide, a growth factor or growth factor-related peptide, gastrin, glucagon, growth hormone-releasing factor, somatostatin, a GTP-binding protein fragment, inhibin, insulin, interleukin, lutenizing hormone-releasing hormone, magainin, melanocyte-stimulating hormone, a morphiceptin, a neuropeptid-Y, a neuromedin, neuropeptide-Y, an opioid peptide, oxytocin, a pancreatic polypeptide, a 30 parathyroid hormone, a vasoactive intestinal polypeptide, Peptide YY, substance P,

-12-

thyroid-releasing hormone, a toxin, vasopressin, and fragments, derivatives, and analogs thereof.

Peptides useful in the invention include those whose sequences differ from the wild-type peptide sequence by only conservative amino acid substitutions. For example, one amino acid may be substituted for another with similar characteristics (e.g. valine for glycine, arginine for lysine) or by one or more non-conservative amino acid substitutions, deletions, or insertions which do not abolish the peptide's biological activity. Other useful modifications include those which increase peptide stability. For example, the peptide may contain one or more non-peptide bonds (which replace a corresponding peptide bond) or D-amino acids in the peptide sequence.

Other peptides which may be used include those described in the Peninsula Laboratories Inc. catalogue, 1992-1993; SIGMA-Peptides and Amino Acids catalogue, 1993-1994; and PIERCE, Catalog & Handbook, Life Science & Analytical Research Products, 1994, the contents of each of which are incorporated herein by reference.

The light-emitting moiety can be any moiety which emits an optical field following excitation. Preferably, the moiety is selected from the group consisting of fluorescein, FTC, Texas Red, phycoerythrin, rhodamine, carboxytetramethylrhodamine, DAPI, indopyra dyes, Cascade blue coumarin, NBD, Lucifer Yellow, propidium iodide, a porphyrin, BODIPY, CY¹, CY⁵, CY⁹, and derivatives thereof. Other light-emitting moieties used in labelling or other applications may be attached to the compound in place of the above. For example, suitable light-emitting moieties are described in Molecular Probes, Handbook of Fluorescent Probes and Research Chemicals, 1992-1994; and Richard P. Haugland et al., "Design and Application of Indicator Dyes", Noninvasive Techniques in Cell Biology: 1-20, Wiley-Liss Inc., (1990), the contents of each of which is incorporated herein by reference.

In general, these light-emitting moieties possess at least one side group capable of reacting with amino acids to form chemical bonds. Such side groups include indoacetamide, maleimide, isothiocyanate, succinimidyl ester, sulfonyl halide, aldehyde, glyoxal and hydrazine derivatives. Amino acids including alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine,

-13-

lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine may be labelled in this fashion.

In order to retain substantial biological activity and affinity for its receptors, the peptide moiety is attached to the light-emitting moiety by a -(CX)- bond. This bond can include groups such as C=O, C=S, CH(OH), C=C=O, C=NH, CH₂, CHO, CHOR, CNR, CH-R, and C-R₁R₄, wherein each R, R₁, and R₄, independently, is H or a C1-C6 branched or unbranched, substituted or unsubstituted, alkyl.

Fluorescent compounds selected to have high biological activities have a number of uses. For most applications, the compound is first contacted with the sample of interest. The compound is then incubated with the cells or tissues of the sample for a select time period and allowed to interact with the receptor corresponding to the compound's peptide.

Once the peptide is bound to the desired receptor sites, the labelled sample is imaged using standard techniques known in the art. For example, conventional microscopy methods, such as fluorescence or confocal microscopy, may be used to optically excite and then detect emission from the labelled receptors. Other imaging techniques which may be used with the fluorescent peptides include atomic force microscopy, fluorescence polarization spectroscopy, and fluorimetry.

Using the above techniques, small-scale features in the cell which normally would be difficult to detect are observed. For example, these techniques allow visualization of intracellular receptor sites. Moreover, labelled peptides participating in peptide-receptor interactions can be monitored to determine the location of receptors in cells or tissues, to allow quantification of receptors, to determine receptor affinity for various unknown ligands (drug screening), and to identify various populations of cells endowed with peptide receptors. Other applications include receptor sorting using FACS (fluorescence-associated cell sorting) and measurement of serum peptide levels using FIA (fluorescent immunoassays) either *in vivo* or *in vitro* for research or diagnostic purposes. In general, techniques which may utilize the compounds of the invention include, without limitation, flow cytometry, cell sorting (for example, to isolate populations of cells bearing a receptor of interest), tumor marking, competitive binding assays for drug

-14-

screening, fluorescent immunoassays, and other *in vitro* experimental techniques involving compound labelling according to techniques known in the art.

The following Examples are used to more particularly point out the synthesis, selection methods, and use of fluorescent peptides having substantial biological activity.

5 **Examples**

Example 1 - Fluorescent Labelling of Galanin and Endothelin

Twenty five μ g of galanin and 20 μ g of endothelin purchased from Peninsula Laboratories Inc. (San Carlos, CA) were dissolved in separate solutions of 40 μ l of 50mM bicarbonate buffer (NaHCO_3), pH 9.3, to a final dilution of 0.8 mM, or 10 μ l of the same in the case of endothelin. NHS-fluorescein (N-hydroxy-succinimidyl ester) from Pierce Chemical Company (Rockford, Illinois) was dissolved in 100 μ l of DMSO. 50-100 μ l of this stock NHS-fluorescein (2.1 μ mol) was added while mixing the peptide solution. The sample was then placed on ice, incubated for one hour at pH 9.3, and then brought to pH 8 by the addition of 500 mM Tris HCl. Incubation was allowed to proceed for the next 18 hours at 4°C.

Following incubation, unreacted fluorescein was removed using G-50 column chromatography (Pharmacia Biotech, Uppsala, Sweden). Biologically active and inactive compounds were eluted with 0.1 M phosphate buffered saline (PBS) at pH 7.4 by spinning the column in a table-top centrifuge at 3000 rpm for 10 minutes. The eluent was dissolved and incubated with known quantities of rat renal membrane homogenates for endothelin, and rat brain homogenates for galanin. The components of these assays were prepared according to standard techniques, with receptor binding monitored in a Beacon™ fluorescence polarization apparatus from Panvera Corp.

25 After allowing binding to occur over a 60-minute period for endothelin and galanin, membranes were precipitated from solution by centrifugation at 3000 rpm for 5 minutes at 4°C. Membranes were then resuspended in PBS and incubated with a solution equivalent to 0.5 M NaCl or 0.2 M acetic acid at pH 3.1 to strip surface-bound fluorescent peptides from their receptors on the cell surface. Using this method, the biologically active compounds were then collected for amino acid analysis.

30 The sites of attachment of fluorescein to endothelin and galanin were confirmed to be at, respectively the ninth amino acid (i.e., lysine) on the epsilon amino group and the

-15-

fifth amino acid residue (lysine) on the epsilon amino group. The molar ratio of fluorescein to peptide was confirmed to be 1:1 in each case.

Competition binding with radiolabelled endothelin and galanin indicated that the peptides had maintained their biological activity and retained a high affinity for their respective receptors. The IC_{50} for unlabelled galanin, as compared to fluorescent galanin, was 1.75 nM versus 8.86 nM. The IC_{50} is related to the K_i by the formula $IC_{50} = K_i (1 + F_i/K_d)$, where F_i is the concentration of the free labelled ligand and K_d is the dissociation constant for the labelled ligand. The K_i for this compound was 1.06 nM versus 5.36 nM. These results indicate a high degree of retention of biological activity.

10 Example 2 - Fluorescent Opioids

As described above, fluorescent opioid peptides can include linker groups to maintain their biological activity. In a particular example, dermorphin, a mu opioid receptor agonist, was originally isolated from the skin of a frog (*Phylomedusa sauvagei*). An analogue of this peptide, [Lys7]dermorphin (NH_2 -Tyr-Dala-Phe-Gly-Tyr-Pro-Lys-C- NH_2), has a very high affinity for the mu opioid receptor, and has a high specificity for the mu receptor when compared to the delta opioid receptors (Negri et al., 1992. Proc. Natl. Acad. Sci. USA 89:7203). Another peptide, deltorphin 1 (NH_2 -Tyr-Dala-Phe-Asp-Val-Val-Gly-C- NH_2), also isolated from the skin of another frog (*Phylomedusa bicolor*) is an agonist with high affinity and selectivity for delta opioid receptors. Structure-activity studies of opioid peptides suggest that the amino terminus of the peptide is necessary to maintain receptor binding and for conferring overall opioid specificity.

20 The deltorphin 1 and [Lys7]dermorphin peptides were modified by adding an linker molecule; this process enabled the coupling of a fluorophore to a previously unreactive or less reactive carboxy terminus amino acid site. The C-terminal amide function (-CONH₂) was substituted by an aliphatic chain ending with a primary aminopentyl group (-CONH-(CH₂)₄-NH₂). The corresponding peptides were then labelled, respectively, on their single amino group with fluorophores.

Preparation of Opioid Precursors

30 The modified opioid peptides described below were prepared by solid-phase synthesis on a standard Merrifield resin including reticulated polystyrene with 1% divinyl benzene. The aminopentyl group was grafted on the C-terminal amino acid by aminolysis

-16-

of the peptide resin with 1.5 diaminopentane as described by Goldstein et al., Proc. Natl. Acad. Sci. 85:7375 (1988), the contents of which are incorporated herein by reference. First, the amino acids which are side-chain protected and activated on their carboxylate groups are attached to the resin in a sequential fashion starting from the C-terminus and ending on the N-terminus. The bond between the resin and the peptide is an ester linkage formed from an OH group of the resin and the carboxyl group of the last amino acid.

5 Using acid hydrolysis, the ester bond between the peptide and resin is then broken in order to introduce the aminopentyl linker group. This process liberates a peptide with a free COOH at the C-terminus. Acid hydrolysis includes incubating the peptide with 10% (v/v) 1.5 diaminopentane in methanol for 60-72 hours at 25°C. This cleaves the ester linkage and replaces it with an amide bond including the C=O moiety of the peptide and one of the amino groups from the 1.5 diaminopentane (either group is acceptable since the molecule is symmetrical).

10 The amino acid side chains of the peptide are then deprotected by treating the peptide with liquid hydrogen fluoride. Ten milliliters of hydrogen fluoride per gram of peptide was used at 0°C for 45 minutes in the presence of p-cresol as scavenger. After evaporation of the hydrogen fluoride, the crude reaction mixture is precipitated with diethylether, washed, dried, dissolved in AcOH and lyophilized. The product was then purified by HPLC using a silica C₁₈ column (5-25μm, 100A) 10 nm x 250 nm (Althosphere, ODS, Beckman) eluted with 0.1% TFA with a linear gradient of 25% to 20 70% CH₃CN/A for 30 minutes at a flow rate of 40 ml/min, and optically detected at 210 nm using ultraviolet absorption spectroscopy.

15 All fractions containing the target compound were individually analyzed by HPLC. Fractions demonstrating sufficient purity were pooled and lyophilized. The final products were identified and monitored for purity and identity using analytical HPLC and electron-spin mass spectral analysis. After filtration of the resin, the protected peptide is dissolved in DMF and concentrated with a rotary evaporator. The product is extracted in DCM, with the excess diaminopentane eliminated with KHSO₄ (0.01M) washings. After evaporation, the peptide is precipitated with diethylether and dried.

-17-

Preparation of Fluorescent Opioids

Opioid precursors described above were reacted with the N-hydroxysuccinimide (NHS) esters of the following fluorophores: Fluorescein, BODIPY 503/512, and BODIPY 576/589 (Molecular Probes, Eugene Oregon). These three reagents were mixed in different solutions (2 μ moles in 400 μ l of dimethyl sulfoxide) and were individually incubated with the deltorphins DLT-1 SAPA and [K7] DRM SAPA (2 μ moles) in a final volume of 1 ml of Borate/Phosphate buffer (pH 8.5) for 3 hours at 4°C. The different derivatives were purified by HPLC on a C₁₈ column (10 mm X 250 mm, Ultrasphere, ODS, Beckman) eluted in TFA (0.1%) with a linear gradient from 20% to 60% over an 80-minute time period. Several fluorescent peaks were identified and tested for their ability to displace the specific binding of iodinated analogues of DLT-1 SAPA and [K7]DRM SAPA to the delta and mu opioid receptors, respectively.

The peptides were purified and then subjected to mass spectroscopy for the determination of the molar ratio of the fluorophore-to-peptide labeling. These studies indicated that all peptides were labelled with a single fluorophore. The sequence of each peptide, as well as the position of the fluorophore along the amino acid chain, were determined by Edman's degradation. Peptide sequencing indicated that none of the peptides were labelled on the α -amino group. In addition, no lysine residue could be detected in position 7 for peptide peaks 3 and 5, indicating that these peptides were labelled by a fluorescent group on the lysine side chain. All other peptides were labelled on the amino group of the carboxy-terminus aminopentyl linker.

The biological activity of the peptides was examined by measuring their ability to displace specific binding of iodinated DLT-1 SAPA and [K7]DRM SAPA to rat mu and delta opioid receptors expressed by transient transfection in COS cells. Iodinated analogues of DLT-1 SAPA and [K7]DRM SAPA (50 000-200 000 cpm) were incubated with delta and mu opioid receptors (5-20 μ g) respectively during 30 minutes at 25°C in 0.25 ml of 0.2% BSA and 50 mM Tris-HCl (pH 7.5). The incubation medium was then diluted in 3 ml of ice-cold incubation buffer and filtered under reduced pressure on GF/C filters presoaked in 0.3% PEI-HCl (pH 7.5). Filters were rinsed by 2X3 ml of ice-cold incubation buffer and counted in a gamma counter. The results of these pharmacological binding experiments are summarized in Table 1.

-18-

Fluorescent analogues were also tested for their ability to selectively label mu and delta opioids receptors on COS cells by fluorescent microscopy. Cells in suspension were incubated for 30 minutes in Earle's buffer containing 0.2% BSA and 10 nM BODIPY 513/512 DLT-1 5APA. Cells were spun down, air dried, and then examined by confocal microscopy. Labeling with the fluorescent derivative appeared as punctate labeling of the cell surface membrane and cytoplasm.

5 **Table 1 – Binding Properties of Fluorescently Labelled Opioid Peptides**

Fluorescent Peptide	Molecular Weight	IC50 (nM) delta	IC50 (nM) mu
DLT-I (Deltorphin)		2.3	1200
ω-BODIPY 503/512 DLT-I 5APA	1084	2	1400
ω-BODIPY 576/589 DLT-I 5APA	1121	2	450
ω-FL DLT-I 5APA	1168	26	>1000
[Lys7]DRM (Dermorphin)		0.9	740
ω-BODIPY 503/512 [K7]DRM 5APA	1177	10	0.6
ω-BODIPY 576/589 [K7]DRM 5APA	1214	21	1
ω-BODIPY 503/512 [R7]DRM 5APA	1205	7.2	0.6
ω-FL [K7]DRM 5APA	1261	116	4.8
ω-FL [R7]DRM 5APA	1289	56	3.6
ε-FL [K7]DRM 5APA	1261	436	11
ε-BODIPY 503/512 [K7]DRM 5APA	1177	2.6	0.7
ε-BODIPY 576/589 [K7]DRM 5APA	1214	14	1.8

10 **Example 3. Fluorescent peptide labelling of peptide receptors on fresh frozen tissue sections**

15 Female Sprague Dawley rats were sacrificed by decapitation, and their brains snap-frozen in isopentane at -40°C. Frozen sections of 20µm from the rat kidney and brain

20

25

-19-

were cut on a cryostat at -20°C and thaw-mounted on gelatin-coated slides. The sections were dried in a desiccator overnight at -20°C.

Kidney sections were incubated in 500ml of 10mM sodium phosphate buffer (pH 7.4) containing 150 mM NaCl, 5 mM Na₂-EDTA, and 0.02% NaN₃, to remove any 5 endogenous ligand. For fluorescent endothelin labeling, kidney sections were preincubated for 15 minutes in 20 mM HEPES buffer (pH 7.4) containing 135 mM NaCl and 2 mM CaCl₂. The sections were then incubated with 2 nM of fluorescent endothelin in 20 mM HEPES buffer (pH 7.4) containing 135 mM NaCl, 2 mM CaCl₂, 0.2% BSA, and 0.01% bacitracin for 2 hours at room temperature. For fluorescent galanin labeling, 10 brain sections from the septal region of the forebrain were incubated with 2 nM of fluorescent galanin in 20 mM HEPES buffer (pH 7.4) containing 5 mM MgCl₂, 0.1% bacitracine, 1mM EDTA, 1% BSA for 45 minutes at room temperature.

After incubation, all rat tissue sections were transferred through 4 successive 1-minute washes of PBS buffer (pH 7.4) at 4°C. The slides were then rapidly dried under a 15 cold stream of air and examined using confocal laser scanning microscopy (CLSM) to observe the binding of the fluorescent peptides. Sections were initially examined on a Leica epifluorescence photomicroscope operating with a high-pressure 100 Watt mercury arc lamp; the appropriate dichroic filter combination for the excitation (485 nm) and emission (520 nm) wavelengths of fluorescein was employed to improve the signal-to- 20 noise ratio of the fluorescence signal. Selected portions of the sections were further scanned using a Leica CLSM (St. Laurent, Quebec, Canada) composed of a Leica Diaplan inverted microscope equipped with an argon ion laser (488 nm) having an output power of 2-50 mW. All computer-generated images (i.e., Figs. 7B-10B) and processing operations were carried out using the Leica CLSM software package.

25 Referring now to Figs. 5A, 5B, 6A, and 6B, sections of rat kidney and brain sections incubated with fluorescent endothelin and galanin demonstrated discreet apple-green fluorescent labeling when monitored with the CLSM. Overall, the distribution pattern of fluorescent labeling conformed to that previously determined using radiolabelled analogs of the above peptides. In particular, the experiments indicated that 30 only areas known to contain receptors were labelled while nearby areas devoid of receptors were completely unlabelled. This finding suggests that the compounds of the

-20-

invention retain the peptides' high specificity for their receptors. In addition, all fluorescent peptide labeling was abolished by incubation with 100-fold excess of unlabelled peptide, further indicating that labeling with the compounds of the invention was selective for the peptides' receptors.

5 Figs. 5A and 5B are, respectively, CLSM and computer generated images of fluorescent endothelin binding to 20 μ m-thick sections from the rat cerebellum, a region known to be enriched in endothelin receptors. Within the cerebellum, the labeling was confined to a Purkinje cell layer which, at higher power, appeared concentrated throughout Purkinje cell bodies and large dendrites. The adjacent molecular layer, represented in the bottom portion of the photograph, was completely devoid of labeling. 10 Incubation with 100-fold excess unlabelled endothelin resulted in an absence of labeling.

15 Figs. 6A and 6B are, respectively, CLSM and computer generated images of fluorescent galanin binding to 20 μ m-thick sections from the rat brain septal region at 40X. This region is known to contain galanin receptors. Within the septal area, the labeling was confined to numerous small fusiform neurons and proximal small dendrites, shown in the center and left-hand portions of the images. In the images, the cellular pattern of labeling was diffuse, whereas the dendritic labeling was of higher resolution.

Other embodiments are within the scope of the following claims.

SUBSTITUTE SHEET (RULE 26)

-21-

What is claimed is:

1. A biologically active compound of the formula:



wherein R_1 is a light-emitting moiety;

R_2 is a peptide of between 2 and 200 amino acids and is not neuropeptideneurotensin; and

X is selected from the group consisting of $=O$, $=S$.

10 -OH, $=C=O$, $=NH$, -H, -OR, -NR, -R, and $-R_3R_4$, wherein each R , R_3 , and R_4 , independently, is H or a C1-C6 branched or unbranched, substituted or unsubstituted, alkyl.

2. The compound of claim 1, wherein R_2 is selected from the group consisting of adrenocorticotrophic hormone, amylin, an amyloid beta-fragment, an atrial natriuretic peptide, bombesin, bradykinin, cadherin, calcitonin, a calcitonin-gene-related peptide, a 15 casomorphin, a morphiceptin, cholecystokinin, corticotropin-releasing factor, deltorphin, a dermorphin, dynorphin, an endorphin, endothelin, enkephalin, fibronectin, galanin, a gonadotropin-associated peptide, a gonadotropin-releasing peptide, a growth factor or growth factor-related peptide, gastrin, glucagon, growth hormone-releasing factor, somatostatin, a GTP-binding protein fragment, inhibin, insulin, interleukin, luteinizing hormone-releasing 20 hormone, magainin, melanocyte-stimulating hormone, a morphiceptin, a neuropeptideneurokinin, a neuromedin, neuropeptide-Y, an opioid peptide, oxytocin, a pancreatic polypeptide, a parathyroid hormone, a vasoactive intestinal polypeptide, Peptide YY, substance P, thyroid-releasing hormone, a toxin, vasopressin, and fragments, derivatives, and analogs thereof.

25 3. The compound of claim 1, wherein C is bonded to R_1 through an amino residue of an alpha carbon atom.

4. The compound of claim 1, wherein R_1 is bound, through C, to a region of said R_2 peptide which is not involved in said biological activity.

SUBSTITUTE SHEET (RULE 26)

-22-

5. The compound of claim 1, wherein said R₂ peptide binds to a human receptor.

6. The compound of claim 5, wherein said first amino-terminal amino acid residue is N^α-Phe-.

7. The compound of claim 3, wherein R₂ is endothelin and R₁ is bonded, through C, to the ninth amino acid residue of R₂.

8. The compound of claim 7, wherein R₁ is bonded, through C, to the ε-amine group of Lys.

9. The compound of claim 8, wherein R₁ is bonded, through C, to the ε-amine group of Lys.

10. The compound of claim 3, wherein R₂ is galanin and R₁ is bonded, through C, to the fifth amino acid residue of R₂.


11. The compound of claim 10, wherein R₁ is bonded, through C, to the ε-amine group of Lys.

15. The compound of claim 1, wherein R₁ is selected from the group consisting of fluorescein, FTC, Texas Red, phycoerythrin, rhodamine, carboxytetramethylrhodamine, DAPI, indopyra dyes, Cascade blue coumarin, NBD, Lucifer Yellow, propidium iodide, a porphyrin, BODIPY, CY³, CY⁵, CY⁹, and derivatives and analogs thereof.

20. The compound of claim 12, wherein R₁ is attached to C-X through a linking moiety selected from the group consisting of indoacetamide, maleimide, isothiocyanate, succinimidyl ester, sulfonyl halide, aldehyde, glyoxal, hydrazine, and derivatives thereof.

-23-

14. A biologically active compound of the formula:



5 wherein R_1 is a light-emitting moiety;

10 R_2 is a peptide of between 2 and 200 amino acids bound to C by a binding moiety selected from the group consisting of the residues Ala, Arg, Asn, Asp, Cys, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val; and

15 X is selected from the group consisting of =O, =S, -OH, =C=O, =NH, -H, -OR, -NR, -R, -R₁R₄, wherein each R, R₁ and R₄, independently, is H or a C1-C6 branched or unbranched, substituted or unsubstituted, alkyl.

16. The compound of claim 14, wherein R_2 is selected from the group consisting of adrenocorticotrophic hormone, amylin, an amyloid beta-fragment, an atrial natriuretic peptide, bombesin, bradykinin, cadherin, calcitonin, a calcitonin-gene-related peptide, a casomorphin, a morphiceptin, cholecystokinin, corticotropin-releasing factor, deltorphin, a dermorphin, dynorphin, an endorphin, endothelin, enkephalin, fibronectin, galanin, a gonadotropin-associated peptide, a gonadotropin-releasing peptide, a growth factor or growth factor-related peptide, gastrin, glucagon, growth hormone-releasing factor, somatostatin, a GTP-binding protein fragment, inhibin, insulin, interleukin, lutenizing hormone-releasing hormone, magainin, melanocyte-stimulating hormone, a morphiceptin, a neuropeptide, a neurokinin, a neuromedin, neuropeptide-Y, an opioid peptide, oxytocin, a pancreatic polypeptide, a parathyroid hormone, a vasoactive intestinal polypeptide, Peptide YY, substance P, thyroid-releasing hormone, a toxin, vasopressin, and fragments, derivatives, and analogs thereof.

20 17. The compound of claim 15, wherein R_2 is either endothelin or galanin.

25 18. The compound of claim 16, wherein R_2 is not neuropeptide-Y.

-24-

18. The compound of claim 14, wherein R₁ is bound, through C, to a region of said R₁ peptide which is not involved in said biological activity.

19. The compound of claim 14, wherein said R₁ peptide binds to a human receptor.

5 20. The compound of claim 14, wherein R₁ is selected from the group consisting of fluorescein, FTC, Texas Red, phycoerythrin, rhodamine, carboxytetramethylrhodamine, DAPI, indopyra dyes, Cascade blue coumarin, NBD, Lucifer Yellow, propidium iodide, a porphyrin, BODIPY, CY³, CY⁵, CY⁶, and derivatives and analogs thereof.

10 21. The compound of claim 20, wherein R₁ is attached to C-X through a linking moiety selected from the group consisting of indoacetamide, maleimide, isothiocyanate, succinimidyl ester, sulfonyl halide, aldehyde, glyoxal, hydrazine, and derivatives thereof.

15 22. A biologically active compound of the formula:

X

|

R₁ - C - R₂

wherein R₁ is a light-emitting moiety;

R₂ is a peptide of between 2 and 200 amino acids; and

20 X is selected from the group consisting of =O, -OH, =C=O, =NH, -H, -OR, -NR, -R, -R₃R₄, wherein each R, R₃ and R₄, independently, is H or a C₁-C₆ branched or unbranched, substituted or unsubstituted, alkyl.

25 23. The compound of claim 22, wherein R₂ is selected from the group consisting of adrenocorticotrophic hormone, amylin, an amyloid beta-fragment, an atrial natriuretic peptide, bombesin, bradykinin, cadherin, calcitonin, a calcitonin-gene-related peptide, a casomorphin, a morphiceptin, cholecystokinin, corticotropin-releasing factor, deltorphin, a dermorphin, dynorphin, an endorphin, endothelin, enkephalin, fibronectin, galanin, a

gonadotropin-associated peptide, a gonadotropin-releasing peptide, a growth factor or growth factor-related peptide, gastrin, glucagon, growth hormone-releasing factor, somatostatin, a GTP-binding protein fragment, inhibin, insulin, interleukin, lutenizing hormone-releasing hormone, magainin, melanocyte-stimulating hormone, a morphiceptin, a neuropeptide, a neuropeptidomimetic, a neuromedin, neuropeptide-Y, an opioid peptide, oxytocin, a pancreatic polypeptide, a parathyroid hormone, a vasoactive intestinal polypeptide, Peptide YY, substance P, thyroid-releasing hormone, a toxin, vasopressin, and fragments, derivatives, and analogs thereof.

24. The compound of claim 23, wherein R₂ is selected from the group consisting of endothelin and galanin.

25. The compound of claim 22, wherein R₁ is not neuropeptides.

26. The compound of claim 22, wherein C is bonded to R₂ through an amino residue of an alpha carbon atom

27. The compound of claim 22, wherein R₁ is bound, through C, to a region of said R₁ peptide which is not involved in said biological activity.

28. The compound of claim 27, wherein said R₂ peptide binds to a human receptor.

29. The compound of claim 22, wherein R₁ is selected from the group consisting of fluorescein, FTC, Texas Red, phycoerythrin, rhodamine, carboxytetramethylrhodamine, DAPI, indopyra dyes, Cascade blue coumarin, NBD, Lucifer Yellow, propidium iodide, a porphyrin, BODIPY, CY³, CY⁵, CY⁶, and derivatives and analogs thereof.

-26-

30. The compound of claim 28, wherein R₁ is attached to C-X through a linking moiety selected from the group consisting of indoacetamide, maleimide, isothiocyanate, succinimidyl ester, sulfonyl halide, aldehyde, glyoxal, hydrazine, and derivatives thereof.

5 31. A method for generating a biologically active compound of claim 1, comprising:

reacting R₁ and R₂ in an aqueous solution to form a compound mixture; contacting said compound mixture with a receptor for R₂; and isolating from said compound mixture a compound exhibiting biological activity in the presence of said R₂ receptor.

10 32. The method of claim 31, wherein said isolating step comprises binding said compound to said R₂ receptor; releasing said compound from said binding complex; and isolating said biologically active complex.

15 33. A method for generating a biologically active peptide compound of claim 1, comprising:

reacting R₁ and R₂ in an aqueous solution to form a compound mixture; contacting said compound mixture with a receptor for R₂; isolating from the compound mixture a compound exhibiting biological activity in the presence of said R₂ receptor; determining the amino acid position at which said R₁ moiety is bound to said R₂ peptide; and synthesizing said compound of claim 1 by chemically attaching said R₁ moiety to said amino acid of said R₂ peptide.


20 25 34. A method for imaging cell receptor sites comprising contacting candidate cell receptor sites with a compound of claim 1, and detecting said bound compounds as an indication of said cell receptor sites.

-27-

35. A method for cell sorting comprising contacting a population of candidate cells with a compound of claim 1, and isolating cells bound to said compound.

36. A method for flow cytometry comprising contacting a population of cells with a compound of claim 1 and detecting cells bearing receptors on their surfaces by detecting cells bound to said compound.

37. A compound of the formula



wherein R_1 is a light-emitting moiety; R_2 is a peptide of between 2 and 200 amino acids; and X is selected from the group consisting of $=O$, $=S$, $-OH$, $=C=O$, $=NH$, $-H$, $-OR$, $-NR$, $-R$, $-R_3R_4$, wherein each R , R_4 , and R_3 , independently, is H or a C1-C6 branched or unbranched, substituted or unsubstituted, alkyl;

wherein said compound is formed by:


reacting R_1 and R_2 in an aqueous solution to form a compound mixture;

contacting the compound mixture with a receptor for R_2 ;

isolating from the compound mixture a compound exhibiting biological activity in the presence of the R_2 receptor; determining biologically inactive regions of the isolated compound; and

synthesizing said compound by chemically attaching R_1 to an amino acid comprised in said biologically inactive region to form a labelled amino acid, and by attaching other amino acids to said labelled amino acid to form said compound.

38. A compound of the formula:



-28-

wherein R₁ is a light-emitting moiety;

R₂ is a peptide of between 2 and 200 amino acids which is not neurotensin;

R₇ is a C1-C6 branched or unbranched, substituted or unsubstituted, alkyl;

and


5

X is selected from the group consisting of =O, =S, -OH, =C=O, =NH, -H, -OR, -NR, -R, and -R₃R₄, wherein each R, R₃, and R₄, independently, is H or a C1-C6 branched or unbranched, substituted or unsubstituted, alkyl.

39. The compound of claim 38, wherein R₂ is an opioid peptide and R₇ is -

NH(CH₂)₅NH-.

1/5

**FIG. 1****SUBSTITUTE SHEET (RULE 26)**

2 / 5






FIG. 2

SUBSTITUTE SHEET (RULE 26)

3 / 5

**FIG. 3****FIG. 4****SUBSTITUTE SHEET (RULE 26)**




FIG. 5A

FIG. 5B

SUBSTITUTE SHEET (RULE 26)




FIG. 6A

FIG. 6B

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 97/00481

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07K14/575		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 96 31531 A (ADVANCED BIOCONCEPT INC) 10 October 1996 see the whole document	1-39
P, X	WO 97 04311 A (ADVANCED BIOCONCEPT INC) 6 February 1997 see the whole document	1-39
X	EP 0 606 804 A (UNIV MCGILL) 20 July 1994 see examples 1,2	1,3-5, 12,14, 17-20, 22, 25-29, 34,38
	-----	-/-
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.
* Special categories of cited documents :		
"A" document defining the general state of the art which is not considered to be of particular relevance		
"E" earlier document but published on or after the international filing date		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.		
"Z" document member of the same patent family		
Date of the actual completion of the international search	Date of mailing of the international search report	
4 November 1997	13/11/1997	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Authorized officer Cervigni, S	

Form PCT/ISA/210 (second sheet) (July 1992)

page 1 of 2

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 97/00481

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 291 708 A (ZENECA LTD) 31 January 1996 see the whole document see example 2 ---	1-8, 12, 14-20, 22-29, 38
X	EP 0 240 914 A (WAKO PURE CHEM IND LTD) 14 October 1987 see the whole document ---	1-5, 12-15, 17-23, 25-30, 38
X	HAZUM E ET AL: "FLUORESCENT AND PHOTO-AFFINITY ENKEPHALIN DERIVATIVES: PREPARATION AND INTERACTION WITH OPIATE RECEPTORS" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 88, no. 3, 13 June 1979, pages 841-846, XP000578538 see the whole document ---	1, 2, 4, 5, 12-15, 17-23, 25, 27-30, 38, 39
X	PATENT ABSTRACTS OF JAPAN vol. 012, no. 270 (C-515), 27 July 1988 & JP 63 051400 A (DAI ICHI PURE CHEM CO LTD; OTHERS: 01), 4 March 1988. see abstract ---	1, 3-6, 12, 14, 17-20, 22, 25-29, 34, 38
A	STEINKAMP J A: "FLOW CYTOMETRY" REVIEW OF SCIENTIFIC INSTRUMENTS, vol. 55, no. 9, September 1984, pages 1375-1400, XP000652545 see the whole document ---	

Form PCT/ISA210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International	Application No
PCT/CA 97/00481	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9631531 A	10-10-96	AU 6352296 A WO 9704311 A	18-02-97 06-02-97
WO 9704311 A	06-02-97	AU 6352296 A WO 9631531 A	18-02-97 10-10-96
EP 0606804 A	20-07-94	CA 2086453 A	01-07-94
GB 2291708 A	31-01-96	AU 2986395 A EP 0774116 A WO 9603647 A	22-02-96 21-05-97 08-02-96
EP 0240914 A	14-10-87	DE 3781185 A ES 2051702 T JP 63066197 A US 5120644 A	24-09-92 01-07-94 24-03-88 09-06-92

Form PCT/ASA/210 (Patent family annex) (July 1992)